FDA Issues Priority Review Voucher for Rare Pediatric Disease Product Zanvastrov
The FDA announced the issuance of a priority review voucher for the rare pediatric disease product Zanvastrov under provisions of the FD&C Act.
The FDA announced the issuance of a priority review voucher for the rare pediatric disease product Zanvastrov under provisions of the FD&C Act.